• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    DBV Technologies S.A. filed SEC Form 8-K: Results of Operations and Financial Condition

    4/30/25 4:46:05 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DBVT alert in real time by email
    8-K
    00-0000000 true 0001613780 false 0001613780 2025-04-30 2025-04-30 0001613780 us-gaap:CommonStockMember 2025-04-30 2025-04-30 0001613780 dei:AdrMember 2025-04-30 2025-04-30
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    April 30, 2025

    Date of Report (Date of earliest event reported)

     

     

    DBV Technologies S.A.

    (Exact name of registrant as specified in its charter)

     

     

     

    France   001-36697   Not applicable

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    107 avenue de la République

    92320 Châtillon France

      Not Applicable
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: +33 1 55 42 78 78

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Ordinary shares, nominal value €0.10 per share   n/a   The Nasdaq Stock Market LLC *
    American Depositary Shares, each representing five ordinary shares, nominal value €0.10 per share   DBVT   The Nasdaq Stock Market LLC

     

    *

    Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 2.02.

    Results of Operations and Financial Condition

    On April 30, 2025, DBV Technologies S.A. (the “Company”) issued a press release announcing financial results and business highlights for the fiscal quarter ended March 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

     

    Item 9.01

    Financial Statements and Exhibits

    (d) Exhibits

     

    Exhibit

    No.

       Description
    99.1    Press Release issued April 30, 2025
    104    Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: April 30, 2025   DBV TECHNOLOGIES S.A.
        By:  

    /s/ Virginie Boucinha

        Name:   Virginie Boucinha
        Title:   Chief Financial Officer
    Get the next $DBVT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DBVT

    DatePrice TargetRatingAnalyst
    5/29/2025$7.25Sell
    Goldman
    1/4/2023Hold → Buy
    Societe Generale
    12/16/2022Neutral → Sell
    Goldman
    5/10/2022$6.00 → $1.50Buy → Neutral
    Goldman
    12/21/2021$8.00 → $5.00Market Outperform
    JMP Securities
    12/21/2021$14.00 → $10.00Buy
    HC Wainwright & Co.
    9/14/2021Hold → Buy
    Societe Generale
    More analyst ratings

    $DBVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman resumed coverage on DBV Technologies with a new price target

      Goldman resumed coverage of DBV Technologies with a rating of Sell and set a new price target of $7.25

      5/29/25 8:17:33 AM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies upgraded by Societe Generale

      Societe Generale upgraded DBV Technologies from Hold to Buy

      1/4/23 7:23:06 AM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies downgraded by Goldman

      Goldman downgraded DBV Technologies from Neutral to Sell

      12/16/22 7:41:19 AM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Leadership Updates

    Live Leadership Updates

    See more
    • DBV Technologies Reports First Quarter 2024 Financial Results and Business Update

      Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024Appointment of Robert Pietrusko, PharmD to Chief Regulatory OfficerQ1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. The quarterly financial statements were approved by the Board of Directors on May 7, 2024. Recent

      5/7/24 4:30:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer

      Montrouge, France, October 16, 2023 DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Virginie Boucinha as its Chief Financial Officer, effective November 6, 2023. An experienced financial and operations executive, Virginie will report directly to Daniel Tassé, Chief Executive Officer, and serve as a member of the Executive Committee. "I am pleased to welcome Virginie to the DBV Executive Committee to lead our global financial organization," said Daniel Tassé, Chief Executive Officer, DBV Tech

      10/16/23 2:00:00 AM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors

      Montrouge, France, October 3, 2022 DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced that Mr. Timothy E. Morris, Independent Director and Member of the Audit Committee of the Board of Directors ("the Board"), was appointed as Chairperson of the Board's Audit Committee in replacement of Ms. Viviane Monges, who resigned from the Board effective October 3, 2022. DBV also announced the Board's provisional appointment of Ms. Daniele Guyot-Caparros as Independent Director to fill Ms. Monges' vacancy, effective October

      10/3/22 4:30:00 PM ET
      $AQST
      $DBVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $DBVT
    SEC Filings

    See more
    • SEC Form 8-K filed by DBV Technologies S.A.

      8-K - DBV Technologies S.A. (0001613780) (Filer)

      6/25/25 4:32:27 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by DBV Technologies S.A.

      S-8 - DBV Technologies S.A. (0001613780) (Filer)

      6/24/25 4:06:11 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by DBV Technologies S.A.

      8-K - DBV Technologies S.A. (0001613780) (Filer)

      6/11/25 4:05:24 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

      Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal InvestigatorAdditional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin® Peanut patc

      6/25/25 4:15:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies to Participate in Upcoming EAACI Congress 2025

      Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 13 – 16, 2025, in Glasgow, United Kingdom. DBV will present two posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presented during the scientific sessions will describe the reduced rate of reactions from accidental peanut consumption (APC) with the VIASKIN® peanut patch versus placebo in Year 2 of the Company's EPITOPE open-label extension (OLE) trial, as w

      6/12/25 4:05:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting

      Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company (the "Company"), held its Combined General Meeting (the "General Meeting"). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company's shareholders approved all resolutions submitted by the Board of Directors. The resolutions and the voting results are posted on the Investors/Annual General Meetings section of the Company's website: https://dbv-technologies.com/events/2025-annual-general-meeting/. About DBV TechnologiesDB

      6/11/25 4:30:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Tasse Daniel bought $14,188 worth of Ordinary Shares (17,094 units at $0.83) (SEC Form 4)

      4 - DBV Technologies S.A. (0001613780) (Issuer)

      3/11/24 4:15:38 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ndu Adora bought $1,624 worth of Ordinary Shares (1,825 units at $0.89) (SEC Form 4)

      4 - DBV Technologies S.A. (0001613780) (Issuer)

      2/8/24 5:02:03 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Mohideen Pharis sold $730 worth of Ordinary Shares (397 units at $1.84), decreasing direct ownership by 0.36% to 110,113 units (SEC Form 4)

      4 - DBV Technologies S.A. (0001613780) (Issuer)

      5/27/25 4:10:06 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Epic Bpifrance claimed ownership of 10,898,595 units of Ordinary Shares (SEC Form 3)

      3 - DBV Technologies S.A. (0001613780) (Issuer)

      5/20/25 4:01:38 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Bpifrance Investissement S.A.S. claimed ownership of 226,133 units of Ordinary Shares (SEC Form 3)

      3 - DBV Technologies S.A. (0001613780) (Issuer)

      4/24/25 4:01:16 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by DBV Technologies S.A.

      SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

      11/14/24 4:55:56 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by DBV Technologies S.A. (Amendment)

      SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

      2/14/24 8:56:45 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by DBV Technologies S.A. (Amendment)

      SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)

      2/14/24 4:06:12 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DBVT
    Financials

    Live finance-specific insights

    See more
    • DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old

      Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal InvestigatorAdditional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin® Peanut patc

      6/25/25 4:15:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

      Châtillon, France, January 8th, 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN® Peanut patch in toddlers 1 – 3 years through 36 months 68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12No treatment-related anaphylaxis or serious treatment-related Treatment-Emergent Adverse Events (TEAEs) occurred in year three of EPITOPE OLE    DBV also announced daily patch wear time data from EPITOPE that is supportive of the Company's proposed labeling approach shared with FD

      1/8/25 4:05:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

      Châtillon, France, December 11th, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old DBV and FDA aligned on key study design elements for the COMFORT Toddlers study in 1 – 3 year-olds, including study size and wear time collection methodology and analysis COMFORT Toddlers study on-track to initiate in 2Q 2025Viaskin Peanut patch BLA submission for the Toddlers indication anticipated for 2H 2026 FDA confirmed criteria for post-marketing confirmatory study in toddlers 1 – 3 years-oldCompany to host investor webcast today at 5:00pm ET DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, tod

      12/11/24 4:05:00 PM ET
      $DBVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care